No products in the cart.
Pre-made Stamulumab benchmark antibody (Whole mAb, anti-MSTN/GDF-8 therapeutic antibody, Anti-GDF8/MSLHP Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-INN-999
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-MSTN/GDF-8 therapeutic antibody (Pre-made Stamulumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Stamulumab (MYO-29[1]) is an experimental myostatin inhibiting drug developed by Wyeth Pharmaceuticals for the treatment of muscular dystrophy (MD). Stamulumab was formulated and tested by Wyeth in Collegeville, Pennsylvania.[2] Myostatin is a protein that inhibits the growth of muscle tissue, stamulumab is a recombinant human antibody designed to bind to and inhibit the activity of myostatin.[3]
| Products Name (INN Index) | Pre-Made Stamulumab Biosimilar, Whole Mab, Anti-MSTN/GDF-8 Antibody: Anti-GDF8/MSLHP therapeutic antibody |
|---|---|
| INN Name | stamulumab |
| Target | MSTN |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – nd |
| VD LC | IgG1 – nd |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Wyeth Pharmaceuticals (Madison NJ USA) / Cambridge?Antibody Technology (Cambridge UK) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | MSTN |
| Package |
Previous slide
Next slide
